← back to search

Timothy L. Lash

Emory Healthcare · US
Area of research
Oncology · Genetics
Research interest
Research interests include Estrogen and related hormone effects, Advanced Causal Inference Techniques, Breast Cancer Treatment Studies, and Global Cancer Incidence and Screening.
h-index
72
citations
21,880
works
552
NIH funding
primary concept
Medicine
email

Recent publications

If You Want to Know the End, Look at the End.
2026cited by 0position: contributordoi
Lack of relationship between posttraumatic stress disorder and coronary atherosclerotic burden among twin veterans from the Vietnam era.
2026cited by 0position: contributordoi
CYP2D6 Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis.
2025cited by 7position: contributordoi
Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real-World Evidence.
2025cited by 7position: contributordoi
Accounting for local incidence when estimating rotavirus vaccine efficacy among countries: a pooled analysis of monovalent rotavirus vaccine trials.
2025cited by 1position: contributordoi
Addressing Measurement Error in Intimate Partner Violence Self-report Data Using Multiple Overimputation and Multidimensional Quantitative Bias Analysis.
2025cited by 1position: contributordoi
Prevalence of Psychiatric Comorbidities in Females With Classic Congenital Adrenal Hyperplasia.
2025cited by 1position: contributordoi
Figure S1 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 1position: contributordoi
Sex Differences in Antihypertensive Medications and PTSD Incidence
Clinical Epidemiology 2025cited by 0position: middledoi
Sex Differences in Antihypertensive Medications and PTSD Incidence.
2025cited by 0position: contributordoi
A registry-based approach for estimating county-level race disparities in breast cancer mortality: an analysis in Georgia.
2025cited by 0position: contributordoi
Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study.
2025cited by 0position: contributordoi
Figure S8 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Figure S4 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Figure S6 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Figure S5 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Figure S3 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Table S1 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Figure S2 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Table S2 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Figure S7 from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Data from <i>CYP2D6</i> Phenotype and Breast Cancer Outcomes: A Bias Analysis and Meta-Analysis
2025cited by 0position: contributordoi
Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation
Circulation 2024cited by 19position: middledoi
Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
Breast Cancer Research 2024cited by 12position: middledoi
Use of quantitative bias analysis to evaluate single‐arm trials with real‐world data external controls
Pharmacoepidemiology and Drug Safety 2024cited by 9position: middledoi
Characterizing Fit-for-Purpose Real-World Data: An Assessment of a Mother-Infant Linkage in the Japan Medical Data Center Claims Database.
2024cited by 5position: contributordoi
Influence of incomplete death information on cumulative risk estimates in US claims data.
2024cited by 5position: contributordoi
Quantitative bias analysis methods for summary-level epidemiologic data in the peer-reviewed literature: a systematic review
Journal of Clinical Epidemiology 2024cited by 5position: contributordoi
Association of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort
JAMA Neurology 2023cited by 124position: middledoi
Pragmatic considerations for negative control outcome studies to guide non‐randomized comparative analyses: A narrative review
Pharmacoepidemiology and Drug Safety 2023cited by 28position: middledoi

Grants

RUI: New Porphyrinoid Architectures with Extended Conjugation Pathways
NSF2247214$463,1492023–2026PIRePORTER
RUI: Aromaticity, Tautomerization and Metalation of Carbaporphyrinoid Systems
NSF1855240$339,9992019–2023PIRePORTER
RUI: Carbaporphyrins, Carbachlorins and Related Conjugated Macrocycles
NSF1465049$320,0002015–2020PIRePORTER
RUI: Carbaporphyrins, Neo-Confused Porphyrins and Related Systems
NSF1212691$300,0002012–2016PIRePORTER
Synthesis of Highly Modified Porphyrinoid Systems
NSF0911699$275,0002009–2013PIRePORTER
Carbaporphyrins and other highly modified porphyrinoid systems
NSF0616555$366,0002006–2011PIRePORTER
Porphyrins, Carbaporphyrins and Related Conjugated Macrocycles
NSF0134472$273,0002002–2005PIRePORTER
Synthesis of Novel Porphyrinoids by the "3 + 1" Approach
NSF9732054$210,0001998–2002PIRePORTER
Synthesis of Cycloalkanoporphyrins and Related Highly Conjugated Systems
NSF9500630$195,0001995–1998PIRePORTER
Synthesis of Novel Porphyrins with Exocyclic Rings
NSF9201149$120,0001992–1995PIRePORTER

Frequent collaborators

· 38 papers (2019–2026)Henrik Toft Sørensen · AstraZeneca (Finland)18 papers (2013–2025)Lindsay J. Collin · Methodist University14 papers (2019–2025)Thomas P. Ahern · National Institute of Environmental Health Sciences14 papers (2022–2025)Thomas P. Ahern · University of Vermont13 papers (2014–2024)Deirdre Cronin‐Fenton · University of Vermont12 papers (2013–2024)Richard F. MacLehose · Tulane University12 papers (2025–2025)Aixin Li · Minnesota Department of Health12 papers (2025–2025)Per Damkier · University of Lausanne8 papers (2013–2022)Peer Christiansen · University of Vermont7 papers (2014–2021)Matthew P. Fox · Boston University7 papers (2016–2024)Deirdre P. Cronin-Fenton · University of Vermont7 papers (2019–2025)Jaimie L. Gradus · Boston University7 papers (2015–2025)Bent Ejlertsen · University of Copenhagen6 papers (2015–2024)Erzsébet Horváth–Puhó · Aarhus University Hospital5 papers (2015–2023)Lisa M. Bodnar · University of Pittsburgh4 papers (2014–2020)Véra Ehrenstein · Amgen (United States)4 papers (2015–2018)Anders Kjærsgaard · University of Vermont4 papers (2017–2021)Per Damkier · Odense University Hospital4 papers (2019–2025)Stephen Hamilton-Dutoit · Aarhus University4 papers (2019–2025)